Biomarkers may yield information relevant to disease outcome on three progressive levels: (i) as measurable endpoints of damage to proteins/amino acids, oxidised lipids, oxidised DNA bases, (ii) as functional markers of, for example, blood flow, platelet aggregation, or cognitive function, and (iii) as endpoints related to specific disease
An exciting example of this is research underway at MIT that is targeting an endoscopic swallowable capsule (smart capsule) delivering gentle electrical pulses to promote gut activity
The South Asian Task Force has defined the rationale for selecting patients with T2DM for GLP-1 RA therapy, which considers whether GLP-1 RA should be used as a monotherapy, dual/triple therapy, or in combination with oral antidiabetic drugs (OADs) with or without insulin [11]
Another benefit of Semaglutide is that it can be used for long-term weight loss management, contributing significantly to improving the quality of life for patients struggling with obesity
The composition of GLP-1 prescribing changed markedly over the period
When patients switch from Ozempic to Rybelsus, they often want to know if Rybelsus oral semaglutide can deliver similar weight-loss benefits